Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity

Study Overview
=================
Brief Summary
-----------------
R2C2 study has shown that abdominal obesity is associated with a cardiac and vascular remodelling in healthy volunteers. This remodelling is correlated with renin-angiotensin aldosterone system (RAAS) activation and/or systemic fibrosis. R2C2 II study is designed to confirm the hypothesis that RAAS is associated with an early remodelling and implicated in the transition to cardiac failure in abdominal obesity.

Detailed Description
-----------------
Follow up of abdominal obesity patients from the R2C2 cohort study.

Official Title
-----------------
Role of the Renin Angiotensin Aldosterone System and Remodeling of the Matrix Cardiac Extra Cellular in the Mechanisms of Transition to Heart Failure in Abdominal Obesity: Prospective Longitudinal Study R2C2 II

Conditions
-----------------
Obesity, Abdominal

Intervention / Treatment
-----------------
* Other: Urine sample
* Other: Blood sample
* Other: Assessment of sleep apnea syndrome
* Other: Electrocardiogram
* Other: Glucose tolerance test
* Other: Echocardiography
* Other: cardiac and abdominal magnetic resonance imaging
* Other: Ambulatory blood pressure monitoring
* Other: Echotracking
* Other: Pulse wave velocity
* Other: Composition of body mass by Dual x-ray absorptiometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being a former member of R2C2 study, abdominal obese group. Having signed the informed consent (refusing to participate to the genetic study is not an exclusion criteria). being affiliated to health insurance scheme. Inclusion Criteria of R2C2 study: Men and women aged between 40 and 65 year's old Caucasian Born or living in France for at least 10 years Presenting an abdominal obesity defined by a waist circumference >94 cm in men and ≥ 80 cm in women, associated or not with untreated hypertension or hypertension treated for less than one year Having signed the informed consent Exclusion Criteria: Subjects unable to understand the information letter Subjects under supervision or guardianship pregnant or lactating woman A contraindication to perform MRI is not an exclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 43 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Abdominal obesity<br>Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions : Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring | Other: Urine sample<br>* dosages on one spot and 24h collection<br>Other: Blood sample<br>* dosages<br>Other: Assessment of sleep apnea syndrome<br> <br> Other: Electrocardiogram<br> <br> Other: Glucose tolerance test<br> <br> Other: Echocardiography<br> <br> Other: cardiac and abdominal magnetic resonance imaging<br> <br> Other: Ambulatory blood pressure monitoring<br> <br> Other: Echotracking<br> <br> Other: Pulse wave velocity<br> <br> Other: Composition of body mass by Dual x-ray absorptiometry<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiac extracellular matrix remodelling | Initial values of cardiac extracellular matrix remodelling biomarkers and the evolution of biomarkers at 3-7 years | 3-7 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac and arterial phenotype | Evolution of cardiac and vascular phenotype in 3-7 years. | 3-7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure, abdominal obesity, RAAS